Brugada syndrome and Drug Challenge Testing
Brugada syndrome was diagnosed in patients with ST-segment elevation with type 1 morphology ≥2 mm in ≥1 lead in the right precordial leads V1, V2, positioned in the 2nd, 3rd, or 4th intercostal space occurring either spontaneously or immediately after drug challenge testing with intravenous administration of SCB class I antiarrhythmic drugs (6). Asymptomatic Brugada syndrome was defined as Brugada syndrome without history of syncope or documented SCD, sudden cardiac arrest, VF, sustained ventricular tachycardia. Symptomatic Brugada syndrome was defined as Brugada syndrome with history of syncope or documented SCD, sudden cardiac arrest, VF, sustained ventricular tachycardia (6).